CanSino's Covid-19 Vaccine Candidate Approved for Military Use in China

  • CanSino's Covid-19 Vaccine Candidate Approved for Military Use in China

CanSino's Covid-19 Vaccine Candidate Approved for Military Use in China

Also, it's unclear what production capacity CanSino has for the experimental drug.

None has yet been approved for commercial use.

Swaminathan said there are now more than 200 candidate vaccines, with 15 at the clinical trial stage.

Ad5-nCoV is one of China's eight vaccine candidates approved for human trials in China and overseas, and it has also been approved for testing in Canada.

CanSino said on Monday that China's Central Military Commission had approved the use of the vaccine on 25 June, for one year. "The Ad5-nCoV is now limited to military use only, and its use can not be expanded to a broader vaccination range without the approval of the Logistics Support Department", CanSino said.

More than half of 17 candidate vaccines identified by the World Health Organization (WHO) that are in clinical evaluation involve Chinese companies or institutes. Swaminathan also stated there are hopes that the vaccines will be ready in 12 -18 months. If successful, this would be the first vaccine to be available in the global fight against the Covid-19 pandemic.

CanSino added that it can not guarantee the vaccine - which had its phase one and two clinical trials done in China - will ultimately be commercialised.

A coronavirus vaccine candidate that showed promise in the early stages of clinical trials has been approved for use with China's military.

A vaccine would see potential profits for the medical and science industry, makers of medicine and researchers. But for the United States or China, it would also be a massive geopolitical victory. Swaminathan said. "They have advanced into phase 2 trials and are planning phase 3 in many countries".

This is the CanSino Biologics-Beijing Institute of Biotechnology product using the "non-replicating viral vector" design.

Since first appearing in China last December, the virus has spread to at least 188 countries and regions.